Article Details

Chiesi buys into Arbor gene editing drug for rare kidney disease | BioPharma Dive

Retrieved on: 2025-10-06 11:13:23

Tags for this article:

Click the tags to see associated articles and topics

Chiesi buys into Arbor gene editing drug for rare kidney disease | BioPharma Dive. View article details on hiswai:

Excerpt

In an interview with BioPharma Dive, Devyn Smith, Arbor's CEO, said his company partnered with Chiesi because it is “very committed” to rare disease ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo